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Abstract
Purpose: In order to improve the quality of care in Cancer
Centers (CC) and designate Comprehensive Cancer Centers
(CCCs), the Organization for European Cancer Institutes
(OECI) launched an Accreditation and Designation (A&D) pro-
gram. The program facilitates the collection of defined data
and the assessment of cancer center quality. This study ana-
lyzes the results of the first 10 European centers that entered
the program.
Methods: The assessment included 927 items divided
across qualitative and quantitative questionnaires. Data col-
lected during self-assessment and peer-review from the 10
first participating centers were combined in a database for
comparative analysis using simple statistics. Quantitative and
qualitative results were validated by auditors during the peer
review visits.
Results: Volumes of various functions and activities dedicated
to care, research, and education varied widely among centers.
There were no significant differences in resources for radiology,
radiotherapy, pathologic diagnostic, and surgery. Differences
were observed in the use of clinical pathways but not for the
practices of holding multidisciplinary team meetings and con-
forming to guidelines. Regarding human resources, main differ-
ences were in the composition and number of supportive care
and research staff. All 10 centers applied as CCCs; five obtained
the label, and five were designated as CCs.
Conclusion: The OECI A&D program allows comparisons be-
tween centers with regard to management, research, care, ed-
ucation, and designation as CCs or CCCs. Through the peer
review system, recommendations for improvements are given.
Assessing the added value of the program, as well as research
and patient treatment outcomes, is the next step.
Introduction
Cancer survival has improved throughout Europe in the past
decade, but large disparities in survival among individual coun-
tries remain, as reported in the latest EUROCARE 5 study.1
Cancer control is an increasing challenge in Europe.
The Organization of European Cancer Institutes (OECI)
stimulates collaboration between cancer institutions in order to
enable mutual learning and improve the quality of cancer care
research and education. It promotes a vision of oncology built
on an integrated model of the cancer research-to-care process.2,3
The OECI Accreditation and Designation Program (A&D)
was launched in 2008 with three objectives: (1) to provide a
comprehensive accreditation for quality oncology care, taking
into account prevention, care, research, education, and net-
working; (2) to develop a database of cancer centers in Europe,
with information on their resources and activities; and (3) to
designate the various types of cancer structures, including
Comprehensive Cancer Centers (CCCs).4 The program ad-
dresses one of the key issues in current cancer care: rapid trans-
lation of research results into clinical and daily practice.4 This
bottom-up approach differs from that of the United States,
where accreditation is provided for by the Joint Commission,
and the recognition of extraordinary translational cancer re-
search programs as a dedicated aspect of CCCs by the National
Cancer Institute.
Publications on the impact of accreditation on hospitals5
and its evaluation as a quality management tool6 are limited;
none have focused on cancer. However, using the Donabedian
structure (processes influence outcome) quality health outcome
models were developed. Structural elements (such as the exis-
tence of a business plan, including aims to achieve, budget
needed, evaluation of the plan), and process elements (such as
use of guidelines, implementation and evaluation of clinical
pathways) were known to be of influence on organizational
performance for other illnesses.7-12 The OECI used this existing
knowledge and translated it into comprehensive cancer care.
Focus on Quality
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Combining the experience of the multidisciplinary comprehen-
sive cancer system in the Netherlands (a bottom-up system: by
professionals for professionals to improve cancer performances
in hospitals), the US designation of cancer centers (CC) for the
health care insurance companies (top down, by the joint Com-
mission), and the already existing quantitative questionnaire
within the OECI, the A&D program was developed by the
OECI.
We report here on a first analysis of the quantitative and
qualitative data and comparative outcome of the A&D Pro-
gram for the first series of 10 European Cancer Centers that
have participated. The objective of this study is to describe the
current landscape of cancer centers that have received accredi-
tation and their compliance with the standards of the OECI
program.
Methods
The OECI Accreditation Program Process
The accreditation process starts with a preliminary designation
(Figure 1) followed by a 6-month self-assessment and a peer
review visit by four auditors from different specialties. Auditors
assess whether the organization meets the quality standards and
to what degree the quality system has been implemented. Once
the center has been reviewed, the OECI delivers a report iden-
tifying quality concerns and recommendations for an improve-
ment plan. If the center is approved, the OECI gives the
accreditation and final designation as a cancer unit, clinical CC;
cancer research center, or CCC (see Designation definitions in
Appendix 1, Data Supplement).
Participants
Participation in the A&D program is voluntary. All OECI
member centers (N  77) were invited to participate in the
program, and 27 accepted initially. Each application is assessed
by the OECI A&D board regarding criteria that should be
fulfilled before entering the program: the center commits to the
completion of the program within the allocated time frame, the
management structure is stable, no major changes (such as
mergers) are expected, and cancer care is performed on an iden-
tifiable unit with a separate budget, management, and organi-
zational structure. All participing center gave informed consent
for the disclosure of their data on an anonymous basis; for this
study, centers have been coded as center A, center B, and so on.
Analysis
The assessment consists of 927 items divided across qualitative
(n 264) and quantitative (n 663) questionnaires, covering
management, prevention, care, infrastructures, human re-
sources, research, and patient centeredness. Items are classified
in organizational performance areas referred to as chapters.
Qualitative chapters include 1: General standards, strategic
plan and general management; 2: Screening, primary preven-
tion, and health education; 3: Care; 4: Research, innovation,
and development; 5: Teaching and continuous education; and
6: Patient related. Quantitative chapters include 1: Infrastruc-
ture for cancer care, 2: human resources, 3: research, and 4:
education.
Qualitative questions are scored from 1 to 4, depending on
the extent of implementation of the standard. The implemen-
tation level is based on Donabedian’s PDCA (plan, do, check,
act) A fully implemented standard received a score of 4 points;
mostly implanted, 3 points; partially implemented, 2 points;
and not implemented, 1 point. In order to calculate the global
score for each chapter, a calculation is made using the number
of times a specific answer (eg, mostly) is given, multiplied by the
points allocated to each answer. That number is divided by the
maximum possible score (total number of answers multiplied
by 4).
Qualitative data are represented in two superimposed spider
diagrams gathering the overall information for each center, as
assessed during self-assessment and by the auditors (Appendix
Figure A1, online only). Information includes the size of the
gaps among the six organizational performance areas (chapters);
No. of beds: < 20
No. of specialists: 0 and
No. of patients: 0 and
No. of scientific publications: > 40
Budget for research: > 500 k€ and
Budget care: < 500 k€
If no
If yes
Cancer
Research
Center
No. of beds and ambulatory day
  care beds: < 50 or
No. of specialists: < 30 or
No. of patients: < 500 or
No. of scientific publications: < 10
and
Center covered by radiotherapy 
  and medical oncology or 
  surgical oncology
Cancer unit, clinical cancer center,
 or Comprehensive Cancer Center
If yes
Cancer
unit
If no
Budget for care: > 5,000 k€
Budget for research: > 3,000 k€
No. of beds and ambulatory day
  care beds: > 100
Active clinical trials: > 50
No. of scientific publications: > 30
No. of scientific publications with
  impact factor over 10: > 17
Clinical cancer center or 
Comprehensive Cancer Center
If no
Clinical cancer center or 
Comprehensive Cancer Center
If yes
First selection
Comprehensive
Cancer Center
Figure 1. Preliminary designation decision tree.
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the important categories of performance, as well as concentra-
tions of strengths and weaknesses; and how the CC staff has
evaluated the organizational performance areas compared with
the auditor’s scorings. Data are collected during self-assessment
and peer review on the A&D Web tool (http://oeci.
selfassessment.nu/cms) and aggregated in a single database to
allow for comparisons among centers.
Results
Ten cancer centers participated in the program between 2008
and 2012, and all initially applied as CCCs. Two identified as
academic institutions, seven as public/nonprofit, and one as
private.
Infrastructures and Activities
There is wide difference in the reported number of new patients
with cancer per year: Centers C indicated 2,481 new patients;
this figure increases to 11,594 for center J (median 6,890), as
shown in Table 1.
However, numbers for use of inpatient beds do not follow
the same distribution, ranging from 15 new patients per bed to
59 new patients per bed. CCs with a number of new patients
above the median have more than 30 new patients per bed,
whereas centers with a number of new patients below the me-
dian treat 13 to 18 new patients per bed.
Regarding ambulatory care, we again see a wide distribution.
Centers that treat fewer than 10,000 new patients show a varied
ratio of new patients per bed, ranging from 80 to 221, whereas
the three centers with more than 10,000 new patients have a
ratio of 130 new patients per bed.
There are also differences in radiotherapy and radiology re-
sources: all centers perform brachytherapy, and most centers (7
of 10) perform intensity-modulated radiotherapy. However,
only two centers perform intraoperative radiotherapy, and two
have access to proton therapy resources. Five centers perform
stereotactic radiotherapy.
Except center I (7344 new patients), which hosts 34 differ-
ent radiology machines, all centers are equipped with five to 10
different facilities. Of note, however, center I is a CC within a
general university hospital, and the radiology facilities available
are not dedicated to the CC only.
All centers use laparoscopy and sentinel node techniques.
Common techniques such as laser therapy, radio frequency ab-
lation, are in place in seven of the centers. Only half of the
centers use intraoperative chemotherapy, hyperthermia, and
isolated limb perfusion.
Only three centers have a bone marrow bank on site. While
two centers do not undertake any bone marrow/stem-cell trans-
plants (BMT), one center performs 195 BMTs in a year.
Clinical Pathways, Guidelines, and
Multidisciplinary Teams
There are large differences in the use of clinical pathways (CPs)
but few in the practice of multidisciplinary teams (MDTs).
Only two centers (A and B) have CPs in place for all patholo-
gies; center G and center D have CPs in place for all pathologies
but one.
Excluding pediatric malignancies CPs (three of 10), and
hematology CPs (five of 10) which exist only in centers provid-
ing such care, CPs have been developed for the most common
cancers (breast, lung, gastrointestinal, gynecological, head and
neck) in more than 90% of centers but are lacking in 30% of
centers for bone, soft tissue, urologic, and skin cancers.
Most centers (except C, F, and G) work with guidelines and
MDTs for all cancers. Centers C, F, and G have guidelines for
all cancers except neuro-oncologic, bone, and soft tissue can-
cers, and MDTs for all cancers except neuro-oncological can-
cers. In 80% of centers, the MDTs are composed of at least a
Table 1. Activities and Infrastructures of the Cancer Centers
Category Center A Center B Center C Center D Center E Center F Center G Center H Center I Center J
Activities
No. of new patients 10,174 2,983 2,481 10,363 7,317 5,319 6,462 2,392 7,344 11,594
No. of inpatient visits for overnight stays 11,470 40,275 6,207 7,556 40,424 4,239 11,715 5,968 23,625 17,248
No. of outpatient visits in consultation 143,586 135,871 121,783 66,441 94,116 43,494 105,818 75,526 127,050 128,643
No. of radiotherapy sessions 2,573 1,210 1,371 7,319 2,278 3,506 2,711 1,425 3,880 2,456
No. of bone marrow and/or stem cell
transplantations per year
97 7 0 100 29 79 0 — 156 195
No. of samplings for tumor diagnosis 18,752 77,314 98,399 5,855 20,663 24,216 20,009 51,328 56,839 17,652
Facilities
No. of ambulatory day care beds or chairs 78 24 31 78 33 43 32 13 79 89
No. of inpatient beds for overnight stays 319 160 186 173 180 288 370 154 241 339
No. of cameras for nuclear medicine 4 2 1 4 3 3 1 3 8 2
No. of operating rooms 7 45 11 4 6 5 7 — 10 10
No. of intensive care beds 8 13 0 6 6 5 12 — 5 28
Total No. of facilities for radiology
(mammography, MRI spectroscopy,
facilities for MRI and
CT scanners
9 10 5 5 5.5 6 5 — 34 4
Abbreviations: CT, computed tomography; MRI, magnetic resonance imaging.
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medical oncologist, surgical oncologist, radiotherapist, radiolo-
gist, pathologist, and nurse.
Human Resources
The number of employees dedicated to cancer care in the
centers, expressed in full-time equivalents (FTE), varies
from 460 to 11,447. The number of FTEs per patient varies
from 2.6 to 21, with a mean of 8.5 (Figure 2A). There was no
correlation between the patient volume of the CC and the
number of FTEs.
The number of FTE nurses per new inpatient or day care
patient is not correlated to the number of FTE physicians per
patient, indicating different types of human resources organi-
zation at the care level. In terms of human resources dedicated
to care, a notable difference is found in the size and composition
of the supportive care team (SCT; Figure 2B). Numbers of SCT
FTEs are not correlated to the number of new patients.
Research Infrastructures and Activities
The number of research-related FTEs (including researchers
and technicians) varies from 17 to 132 in clinical CCs and from
134 to 479 in CCCs, with the highest numbers in center E
(479) and J (370; Figure 2C).
The repartition of staff in different research areas (Figure
2D) seems to be related to the expertise of each center. In the
two centers with the highest number of researchers, most re-
search staff work in (onco)genomics and cell biology (center E)
and in clinical trials and immunology (center J). The number of
ongoing active studies varies from 6 to 252 in clinical CCs and
from 91 to 508 in CCCs, with an overall median number of 91.
Center J (second highest in terms of FTE researchers) had
the highest number of publications with an impact factor 10
(n  112), the highest number of international publications
(661) and patents (50), and a high accrual rate of patients in
trials (19%). Despite having 100 more researchers than center J,
center E did not score as well. In terms of patient’s accrual in
clinical trials, centers could be grouped into two categories: five
centers enrolled 10% of their patients (range 10% to 23.5%),
whereas the other five enrolled  5% (0.07% to 3%).
Education
There are no notable differences in the education resources and
activities such as information centers, medical libraries, educa-
tional courses, and continuing medical education. There is a
difference between CCs and CCCS in the existence of courses
with international audiences.
The centers receive from 0 to 509 medical students per year
and from 24 to 400 student nurses per year. In accordance with
the number of researchers and research production, centers I, E,
and J welcome the highest number of PhD students and pro-
duce the highest number of PhD theses per year.
Qualitative Assessment
Qualitative assessment covers the six organizational perfor-
mance areas described previously. A global score for each chap-
ter was calculated (see Methods for the detail of the calculation).
A graphic representation of this calculation for all centers shows
the results according to both the self-assessment and the peer
review visit (Appendix Figure 1C). For all centers and almost all
areas, the scoring done by the center through self-assessment is
higher than the scoring of the peer review visit; centers A and C
provided the most discordant assessments.
Although patient care scores best among the performance
areas for all centers, important deficiencies can be seen in re-
search (centers A, B, C, F, G, H, and I), education (centers C, F,
and I), and even general oncological management (centers A, C,
F, and H). Centers D, E, and J appear to adequately meet
quality requirements in all areas.
Outcome of the Peer Review Visit
Results of the peer-review with a selection of comments from
auditors are presented in the Data Supplement. Recommenda-
tions cover mainly leadership issues, deliver of care, clinical
decision support, and integration with research. Despite the
existence of MDTs in all centers for most tumor sites, recom-
mendations to improve MDT structure were provided for six of
the 10 centers. Drug prescription system appeared as an area in
need of improvement for five centers.
The consistency between quantitative data and qualitative
findings was assessed. The strength or weakness of departments
such as supportive care, pathology, or clinical research, as as-
sessed by the auditors, is related to the number of staff in those
departments, as can be seen for center B (weakness in SCT).
Centers such as E and J with high levels of research resources
and production were also identified as models for organization
of research integration into care.
Criteria for Designation
Five cancer centers applied for designation as a CCC and
achieved it. Five cancer centers applied for designation as a
CCC but did not achieve it (four of them were designated
clinical CCs and one of them is awaiting designation pending
major changes). For three of the latter, failure to obtain desig-
nation was related to research shortcomings; for the fourth cen-
ter, it was research and care, and for the last it was care alone.
These criteria were either quantitative (mainly the lack of pub-
lications in journals with high impact factor and lack of clinical
trials) or qualitative (lack of integration of research into care or
between laboratories).
The criteria related to care that caused the centers to fail to
achieve designation as a CCC were purely qualitative, and
mainly concerned lack of harmonization between patients and
quality policy and guidelines. The comprehensiveness and clear
dedication of an identifiable integrated structure for cancer
management was a key issue in obtaining CCC designation,
especially for cancer structures in large university hospitals.
Discussion
The objective of this article was to report the global results of
the first series of OECI centers participating in the A&D pro-
gram and to investigate the potential use of the questionnaire
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Saghatchian et al
e346 JOURNAL OF ONCOLOGY PRACTICE • VOL. 10, ISSUE 5 Copyright © 2014 by American Society of Clinical Oncology
D
ow
nloaded from
 jop.ascopubs.org on April 18, 2016. For personal use only. No other uses without permission.
Copyright © 2014 Am
erican Society of Clinical O
ncology. All rights reserved.
data. The data collected allow comparisons between the centers,
especially with regard to patient numbers or tumor type port-
folio.
In terms of care, resources and infrastructures are not homo-
geneous among the centers, especially when results are reported
as the number of patients or activities. Data linked to SCT show
that supportive care remains an area of wide discrepancies. Dif-
ferences are even wider in the research area and clearly allow for
a distinction between CCs and CCCs.
Data about the number of researchers can help define the
critical mass of researchers and the research specialization of a
center; with regard to expenditure, such data can also provide
information on investment priorities and relative overhead per
FTE.
There are some limitations to the study. First, it is likely that
at least some data may have been collected in different ways in
the centers. This could be due to different understanding of the
question or different reporting methods. Furthermore, we be-
lieve that the data should be analyzed in the context of the
different national health systems. For example, the program is
currently ongoing for all cancer centers in Italy, and this will
allow us to assess the program for centers located in the same
cultural, organizational, and regulatory framework.
Several accreditation programs have been developed world-
wide. They consist mainly of general accreditation programs for
hospitals.13 Further accreditations of specific structures, such as
hematopoietic stem-cell transplantation units,14 palliative
care,15 and research tissue banks,16 have been proposed. Some
countries have established tumor-based accreditation sys-
tems.17,18 Finally, many countries have research evaluation pro-
grams, such as the National Cancer Institute in the United
States. However, the OECI offers the only accreditation pro-
gram dedicated to care, research, and education together, assess-
ing the integration of those three aspects for cancer care
specifically in the institutional setting.
The data collected so far are mainly structure and process re-
lated, whereas outcome data are preferred if performance is to be
presented or compared. In oncology, this is an issue because med-
ical records content should be connected to cancer registries in
order to obtain sufficsient long-term follow-up and survival data.
In the present update of the A&D program, an effort to assemble
outcome data will be made. In the literature so far, there is little
evidence of accreditation actually improving patient outcomes, as a
result of either methodological issues in comparing organizational
performance or the “black box” character of the mechanism
through which A&D exerts its effect. Nevertheless, a recent arti-
cle19 showed improved survival and faster adoption of some inno-
vative procedures after peer review of cancer services in general
hospitals.
Because its final goal is to improve quality of care by inte-
gration of high-quality cancer research, the OECI is currently
developing a benchmarking project based on the A&D pro-
gram. The general objective of this project is to benchmark
comprehensive cancer care and yield best practice examples in a
way that contributes to improving the quality of interdisciplin-
ary patient treatment. Indicators are defined and pilot tested in
the centers to measure the outcome and impact of the transla-
tional research carried out in those centers. The A&D program
is in the process of reviewing the standards. A new questionnaire
will be developed in which a division will be made between
mandatory standards and optional standards.
In conclusion, the A&D program has been set up as a re-
sponse to the need to promote integration of research, educa-
tion, and clinical services. Setting up minimum standards of
care and research and designating CCCs is only the first step of
this process. Measuring the translational research and patients’
outcome performed through these centers is the next step.
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Figure A1. Superimposed spider diagrams gathering the overall information for each center, as assessed during self-assessment and by the auditors.
General Management refers to chapter 1: General standards, strategic plan, and general management; Prevention refers to chapter 2: Screening and
primary prevention and health education; Care refers to chapter 3: Care; Research refers to chapter 4: Research; Education refers to chapter 5:
Education and teaching; Patient-related refers to chapter 6: Patient related.
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